BERGENBIO
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
BERGENBIO
Industry:
Biotechnology Pharmaceutical
Founded:
2007-01-01
Address:
Bergen, Hordaland, Norway
Country:
Norway
Website Url:
http://www.bergenbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
150.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome Sitelinks Search Box Euro
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Anjarium Biosciences
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Aprea
Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
Inthera Bioscience
Inthera Bioscience is focused on developing inhibitors of intracellular protein interactions employing a proprietary technology platform.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Numeric Biotech
Numeric Biotech is to build an innovative portfolio of first-in-class treatments that target multiple mechanisms of age related diseases.
OCTIMET Oncology
OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles
Oncopeptides
Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Investinor
Investinor investment in Series D - BerGenBio
Meteva AS
Meteva AS investment in Series D - BerGenBio
Sarsia Seed Management
Sarsia Seed Management investment in Series C - BerGenBio
Investinor
Investinor investment in Series C - BerGenBio
Investinor
Investinor investment in Series B - BerGenBio
Sarsia Seed Management
Sarsia Seed Management investment in Series A - BerGenBio
Investinor
Investinor investment in Series A - BerGenBio
Sarsia Seed Management
Sarsia Seed Management investment in Seed Round - BerGenBio
Birk Venture
Birk Venture investment in Seed Round - BerGenBio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-11 | BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer |
Official Site Inspections
http://www.bergenbio.com Semrush global rank: 10.14 M Semrush visits lastest month: 39
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
